About Nabsys
Nabsys is a company based in Providence (United States) founded in 2004 by Barrett Bready was acquired by Hitachi High-Tech Corporation in August 2024. Nabsys has raised $144.3 million across 15 funding rounds from investors including HHS, Hitachi High-Tech Corporation and NHGRI. The company has 44 employees. Nabsys offers products and services including OhmX Platform, Electronic Genome Mapping, Sample Prep Kit, Nanodetectors, and Bioinformatics. Nabsys operates in a competitive market with competitors including Cepheid, PacBio, Fluidigm, Complete Genomics and GenapSys, among others.
- Headquarter Providence, United States
- Employees 44
- Founders Barrett Bready
- SectorsHealthcareTechnology
- Website nabsys.com
- Social LinkedIn X
- Acquired by Hitachi High-Tech Corporation (Aug 2024)
- Legal Name Nabsys Inc
- Total Equity Funding$144.3M (USD)
in 15 rounds
- Latest Funding Round$13M (USD), Series E
Nov 2022
- InvestorsHHS
& 5 more
- Employee Count44
- Acquired byHitachi High-Tech Corporation
(Aug 2024)
Products & Services of Nabsys
Nabsys offers a comprehensive portfolio of products and services, including OhmX Platform, Electronic Genome Mapping, Sample Prep Kit, Nanodetectors, and Bioinformatics.
Enables whole genome structural variant detection with high resolution.
Facilitates analysis of genomic structural variations for research.
Supports preparation for structural variant detection processes.
Delivers high-resolution electronic detection of DNA variations.
Provides analytical software for interpreting genomic data.
Funding Insights of Nabsys
Nabsys has successfully raised a total of $144.3M across 15 strategic funding rounds. The most recent funding activity was a Series E round of $13 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $144.3M
- Total Rounds 15
- Last Round Series E — $13M
- First Round $1M
(Jun 2007)
- Investors Count 6
Latest 10 of 15 funding rounds of Nabsys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $13M | Series E | – | – | |
| Apr 2022 | $25M | Series E | – | Hitachi High-Tech Corporation | – |
| Oct 2019 | $21M | Series D | – | Hitachi High-Tech Corporation | – |
| Aug 2014 | $25.5M | Series D | – | – | – |
| Mar 2013 | $35.05M | Series D | – | – | |
| Sep 2011 | $10M | Series C | – | – | – |
| Feb 2010 | $7M | Series B | – | – | – |
| May 2009 | $4M | Series A | – | – | |
| Jan 2009 | $2.75M | Series A | – | – | – |
| Aug 2008 | $248,597 | Grant | – | – |
6 investors in total: 6 institutional.
Investors in Nabsys
Nabsys has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Hitachi High-Tech Corporation and NHGRI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life-sciences sectors are managed. | – | baycitycapital.com | San Francisco, United States | |
Seed and early-stage investments in US tech sectors are made. | – | pjc.vc | Boston, United States | |
VC investments are directed toward US and UK companies. | – | slaterfund.com | Providence, United States | |
Operations are maintained across multiple industries by the diversified conglomerate. | 1947 | hitachi-hightech.com | Minato City, Japan | |
Genomics research and educational resources are provided. | 1988 | genome.gov | Bethesda, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Nabsys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nabsys
10 people are tracked at Nabsys (8 in leadership, 2 in team); the tracked headcount is 44.
| Name | Role | Group |
|---|---|---|
Barrett Bready | Founder & CEO | Leadership |
Jennet Toyjanova | Director Of Product Development Management | Leadership |
Bob Hertsenberg | Global Head Of Instrument Sales | Leadership |
Jennifer Davis | VP Technology Development | Leadership |
Jay Sage | Senior Director - Assay Development | Leadership |
Jason Hughes | Vp, Computational Biology | Leadership |
Mel Davey | Sr. Director Of Software Engineering | Leadership |
Elise C. Benson | Director Of Marketing | Leadership |
Yana Sheberla | Senior Software Engineer | Team |
Chandra Meduri | Sr Manufacturing And Quality Systems Engineer | Team |
Complete people profiles for Nabsys
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nabsys
4 dated milestones of Nabsys across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Nabsys is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series E, of $13.0M.
- Exit Acquired by Hitachi High-Tech Corporation.
Competitors of Nabsys
Nabsys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, PacBio, Fluidigm, Complete Genomics and GenapSys, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cepheid.com | 1996 | Sunnyvale, United States | $19.1M | 1,299 | Developer of molecular diagnostic testing solutions | |
| pacb.com | 2004 | Menlo Park, United States | $395M | 649 | Instrument systems and software for single-molecule real-time sequencing are developed. | |
| fluidigm.com | 1999 | San Francisco, United States | $40.53M | 205 | Instruments for life sciences research and applications are developed. | |
| completegenomics.com | 2006 | San Jose, United States | $124.99M | 70 | DNA sequencing platform for human genome analysis is developed. | |
| genapsys.com | 2010 | Redwood, United States | $313.03M | 60 | Provider of DNA sequencing technologies for applied genomic testing and medical sequencing | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems | |
| stratosgenomics.com | 2007 | Seattle, United States | $62.89M | 64 | Nanopore-based single molecule sequencers are developed using SBX technology. | |
| bionano.com | 2002 | San Diego, United States | $124.2M | – | Provider of genome analysis solutions to researchers and clinicians | |
| quantapore.com | 2009 | San Francisco, United States | $50.55M | 17 | Single-molecule nucleic acid sequencing technology is developed using nanopores. |
Detailed competitors of Nabsys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nabsys
The website of Nabsys (nabsys.com) receives about 9.9K visits a month.
- Monthly visits9.9K
▲ 27.6% vs previous month
Latest news on Nabsys
Complete news archive for Nabsys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Nabsys
10 companies that operate in the same segment as Nabsys (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Nabsys
Nabsys was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Nabsys is headquartered in Providence, United States. It is registered at Providence, Rhode Island, United States.
Barrett Bready is the current CEO of Nabsys. They have also founded this company.
Nabsys is a funded company, having raised a total of $144.3M across 15 funding rounds to date. The company's 1st funding round was a Grant of $248.6K, raised on Jun 2007.
Nabsys has 44 employees.
Nabsys was founded in 2004 in Providence, United States, within the biotechnology sector. Solid-state nano detectors are developed by the company for analyzing long DNA molecules at high velocity. Sequence-specific tags are identified on the DNA, with data subsequently validated and characterized through proprietary software tools. Operations center on genome mapping technologies to support sequencing applications.
Nabsys's top competitors include Cepheid, PacBio and Complete Genomics.
Nabsys offers OhmX Platform, Electronic Genome Mapping, Sample Prep Kit, Nanodetectors, and Bioinformatics.
Nabsys has 6 investors. Key investors include HHS, Hitachi High-Tech Corporation, NHGRI, Bay City Capital, and PJC.
Nabsys operates through Nabsys Inc.
Yes. Nabsys was acquired by Hitachi High-Tech Corporation in August 2024.